Balchem Reports Record 2025 Financials with Strong Growth and Launches New Share Repurchase Program
BCPC sits 24% above its 52-week low of $139.17.
Summary
Balchem reported record financial results for 2025, including significant increases in net sales and earnings, alongside the launch of a new, substantial share repurchase program and favorable anti-dumping duties in Europe.
Key Events · Earnings and Guidance · BCPC
-
Record Financial Performance in 2025
Balchem reported record net sales of $1.037 billion (up 8.8% from 2024), gross margin of $370.6 million (up 10.2%), and net earnings of $154.8 million (up 20.5%). Diluted EPS increased to $4.75, up 20.9% from $3.93 in 2024.
-
New Share Repurchase Program Authorized
The Board of Directors approved a new stock repurchase program on December 9, 2025, authorizing the repurchase of up to 4,000,000 shares. In 2025, the company repurchased 684,927 shares for $107.6 million, demonstrating a significant commitment to shareholder returns.
-
Favorable Anti-Dumping Duties in Europe
The European Commission finalized definitive anti-dumping duties ranging from 90.0% to 115.9% on choline chloride imports from China, effective July 1, 2025. This is a positive development for Balchem's Animal Nutrition and Health segment, reducing competitive pricing pressure.
-
EPA Settlement Resolved
BCP Ingredients, a subsidiary, settled alleged Clean Air Act violations with the EPA and DOJ on January 31, 2025, agreeing to pay a $300,000 civil penalty and invest $350,000 in community projects. This resolution was consistent with previously accrued loss contingencies and is not considered material.
Analysis · BCPC · Industrial Applications And Services
Balchem Corporation's 2025 Annual Report on Form 10-K confirms robust financial performance, building on the preliminary results announced in the recent 8-K. The company achieved record net sales, gross margin, and net earnings, driven by strong growth across its Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments. A significant highlight is the approval of a new stock repurchase program authorizing up to 4,000,000 shares, with substantial repurchases already made in 2025, signaling confidence in the company's value and a commitment to returning capital to shareholders. Additionally, the European Commission's final decision to impose anti-dumping duties on choline chloride imports from China is a favorable regulatory development for the Animal Nutrition and Health segment, reducing competitive pressures. The resolution of an EPA settlement with a non-material civil penalty further removes a potential overhang. These factors collectively present a positive outlook for investors, emphasizing strong operational execution and strategic capital management.
At the time of this filing, BCPC was trading at $172.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $139.17 to $183.01. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.